Share
ENDO 2022 saw the presentation of positive clinical data from the open-label extensions (OLEs) of two of the Phase 3 trials of oral octreotide for patients with acromegaly. Amryt is marketing the drug as Mycapssa. Data presented in a late-breaking poster presentation of the 2nd year of the OLE of OPTIMAL (NCT03252353), a randomized, double-blind...
Share
Last summer, the U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes and in adults with type 2 diabetes. The FDA granted approval for insulin glargine-yfgn to Mylan Pharmaceuticals Inc., who is marketing the product as Semglee. Semglee...
Share
Physicians may be able to determine if menopause-related bone loss is already in progress or about to begin by measuring the level of a hormone that declines as women approach their final menstrual period, according to a study recently published in Journal of Bone and Mineral Research. The findings could help physicians determine when, and...
Share
Positive results from the Phase III LINC 4 study have confirmed the efficacy and safety of osilodrostat, an oral therapy for patients with Cushing’s disease. The results were published in The Journal of Clinical Endocrinology & Metabolism. Recordati Rare Diseases is marketing the drug as ISTURISA®. The LINC 4 study augments the efficacy and safety...
Share
A review recently published in Endocrinology offers some new insights on how maternal obesity-associated gestational diabetes (GDM) affects the reproductive health of offspring, discussing possible mechanisms, the latest perceptions, and highlighting areas that need further investigation. The review, by Niharika Sinha, PhD; Gretchen Lydia Walker; and Aritro Sen, PhD, all of Michigan State University in...
Share
A paper recently published in Endocrine Reviews looks to provide readers with an improved understanding in approaches to using hormone therapy to treat menopausal women. The review, by Valerie Flores, MD, and Lubna Pal, MD, of Yale School of Medicine and JoAnn Manson, MD, of Harvard Medical School, points out that hormone therapy remains the...
Share
Postmenopausal women have increased risk of non-alcoholic fatty liver disease due to loss of estrogen from metabolic changes. A high-fat diet further exacerbates the disease, which can progress to cirrhosis and liver failure. Hormone replacement therapy (HRT) is an effective treatment, but it carries increased risk of breast cancer, uterine cancers, and cardiovascular disease. Researchers...
Share
A high-fat diet disturbs the body clock in rat brains that normally controls satiety, leading to over-eating and obesity, according to new research published in The Journal of Physiology. This new research may be a cornerstone for future clinical studies that could restore the proper functioning of the body clock in the brain, to avoid...
